

Supplemental Digital Content 3. Lists of full text articles excluded. (n=33)

(A) Without adequate information (n=17)¹⁻¹⁷;

(B) Without proper control (n=16)¹⁸⁻³³.

1. Badala F. The treatment of branch retinal vein occlusion with bevacizumab.

Current opinion in ophthalmology 2008;19(3): 234-238.

doi:10.1097/ICU.0b013e3282fb7fb0

2. Boyer D, Heier J, Brown DM, Clark WL, Vitti R, Berliner AJ, Groetzbach G, Zeitz O, Sandbrink R, Zhu X et al. Vascular endothelial growth factor trap-eye for macular edema secondary to central retinal vein occlusion: Six-month results of the phase 3 copernicus study. Ophthalmology 2012;119(5): 1024-1032.

doi:10.1016/j.opthta.2012.01.042

3. Boyer DS. Efficacy and safety of intravitreal aflibercept injection (iai) for treatment of macular edema secondary to branch retinal vein occlusion (brvo): 24-week results of the vibrant study. Invest Ophthalmol Vis Sci 2014;55(13)

4. Brown DM, Campochiaro PA, Singh RP, Li Z., Gray S, Saroj N, Rundle AC, Rubio RG, Murahashi WY. Ranibizumab for macular edema following central retinal vein occlusion: Six-month primary end point results of a phase iii study.

Ophthalmology 2010;117(6): 1124-1133.e1121. doi:10.1016/j.opthta.2010.02.022

5. Campochiaro PA, Clark WL, Boyer DS, Heier JS, Brown DM, Vitti R, Kazmi H, Berliner AJ, Erickson K, Chu KW et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: The 24-week results of the vibrant study.

Ophthalmology 2015;122(3): 538- 544. doi:10.1016/j.opthta.2014.08.031

6. Campochiaro PA, Clark WL, Boyer DS, Heier JS, Brown DM, Vitti R, Kazmi H, Berliner AJ, Erickson K, Chu KW et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: The 24-week results of the vibrant study. *Ophthalmology* 2015;122(3): 538-544. doi:10.1016/j.opthta.2014.08.031
7. Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC, Murahashi WY, Rubio RG, BRAVO Investigators. Ranibizumab for macular edema following branch retinal vein occlusion: Six-month primary end point results of a phase iii study. *Ophthalmology* 2010;117(6): 1102-1112.e1101. doi:10.1016/j.opthta.2010.02.021
8. Das T., Narayanan R, Panchal B, Jalali S, Chablani J, Relhan N, Mathai A, Reddy RP, Rani PK, Ali MH. A randomized, double masked, controlled study of efficacy and safety of intravitreal ranibizumab versus bevacizumab in subjects with macular edema secondary to branch retinal vein occlusion. Branvo study. *Invest Ophthalmol Vis Sci* 2014;55(13)
9. Lotfy A, Solaiman KAM, Abdelrahman A, Samir A. Efficacy and frequency of intravitreal aflibercept versus bevacizumab for macular edema secondary to central retinal vein occlusion. *Retina (Philadelphia, Pa)* 2018;38(9): 1795-1800. doi:10.1097/iae.0000000000001782
10. Narayanan R, Panchal B, Das T, Chhablani J, Jalali S, Ali MH. A randomised, double-masked, controlled study of the efficacy and safety of intravitreal bevacizumab versus ranibizumab in the treatment of macular oedema due to branch retinal vein occlusion: Marvel report no. 1. *The British journal of ophthalmology* 2015;99(7): 954-959. doi:10.1136/bjophthalmol-2014-306543

11. Nct. Ranibizumab for macular edema secondary to branch retinal vein occlusion in patients with fair vision. <https://clinicaltrials.gov/show/nct01795209> 2013
12. Nct. Phase i/ii trial to find maximum tolerated dose (mtd) and dose limiting toxicities (dlt) of tlc399 (prodex) in patients with macular edema due to retinal vein occlusion (rvo). <https://clinicaltrials.gov/show/nct02006147> 2013
13. Nct. Suprachoroidal injection of triamcinolone acetonide with ivt aflibercept in subjects with macular edema following rvo. <https://clinicaltrials.gov/show/nct02980874> 2016
14. Pieramici DJ, Rabena M, Castellarin AA, Nasir M, See R, Norton T, Sanchez A, Risard S, Avery RL. Ranibizumab for the treatment of macular edema associated with perfused central retinal vein occlusions. *Ophthalmology* 2008;115(10): e47-54. doi:10.1016/j.opthta.2008.06.021
15. Thach AB, Yau L, Hoang C, Tuomi L. Time to clinically significant visual acuity gains after ranibizumab treatment for retinal vein occlusion: Bravo and cruise trials. *Ophthalmology* 2014;121(5): 1059-1066. <https://doi.org/10.1016/j.opthta.2013.11.022>
16. Tultseva SN, Astakhov YS, Novikov SA, Nechiporenko PA, Lisochkina AB, Ovnanyan AY, Astakhov SY. Alternative ways to optimize treatment for retinal vein occlusion with peripheral capillary non-perfusion: A pilot study. *Arquivos brasileiros de oftalmologia* 2017;80(4): 224-228. doi:10.5935/0004-2749.20170055
17. J. J. Wroblewski, A. Y. Hu. Topical squalamine 0.2% and intravitreal ranibizumab 0.5 mg as combination therapy for macular edema due to branch and

central retinal vein occlusion: An open-label, randomized study. *Ophthalmic surgery, lasers & imaging retina* 2016;47(10): 914-923. doi:10.3928/23258160-20161004-04

18. Austeng D, Morken TS, Bolme S, Follestad T, Halsteinli V. Nurse-administered intravitreal injections of anti-vegf: Study protocol for noninferiority randomized controlled trial of safety, cost and patient satisfaction. *BMC ophthalmology* 2016;16(1): 169. doi:10.1186/s12886-016-0348-4

19. Azad R, Vivek K, Sharma Y, Chandra P, Sain S, Venkataraman A. Ranibizumab as an adjunct to laser for macular edema secondary to branch retinal vein occlusion. *Indian journal of ophthalmology* 2012;60(4): 263-266. doi:10.4103/0301-4738.98701

20. Ding X, Li J, Hu X, Yu S, Pan J, Tang S. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion. *Retina (Philadelphia, Pa)* 2011;31(5): 838-845. doi:10.1097/IAE.0b013e3181f4420d

21. Eter N. Efficacy and safety of ranibizumab 0.5 mg versus dexamethasone 0.7 mg in branch retinal vein occlusion: 6-month results of the comrade-b study. *Invest Ophthalmol Vis Sci* 2015;56(7): 5806

22. Feltgen N, Hattenbach LO, Bertelmann T, Callizo J, Rehak M, Wolf A, Berk H, Eter N, Lang GE, Pielen A et al. Comparison of ranibizumab versus dexamethasone for macular oedema following retinal vein occlusion: 1-year results of the comrade extension study. *Acta ophthalmologica* 2018;96(8): e933-e941. doi:10.1111/aos.13770

23. Hattenbach LO. Efficacy and safety of 0.5 mg ranibizumab compared with 0.7 mg dexamethasone intravitreal implant in patients with branch retinal vein occlusion over 6 months: The comradeb study. *Invest Ophthalmol Vis Sci* 2014;55(13)
24. Hattenbach LO, Feltgen N, Bertelmann T, Schmitz-Valckenberg S, Berk H, Eter N, Lang GE, Rehak M, Taylor SR, Wolf A et al. Head-to-head comparison of ranibizumab prn versus single-dose dexamethasone for branch retinal vein occlusion (comrade-b). *Acta ophthalmologica* 2018;96(1). doi:10.1111/aos.13381
25. Heier JS, Antoszyk AN, Pavan PR, Leff SR, Rosenfeld PJ, Ciulla TA, Dreyer RF, Gentile RC, Sy JP, Hantsbarger G et al. Ranibizumab for treatment of neovascular age-related macular degeneration: A phase i/ii multicenter, controlled, multidose study. *Ophthalmology* 2006;113(4): 633.e631- 634.
doi:10.1016/j.opthta.2005.10.052
26. Hoerauf H, Feltgen N, Weiss C, Paulus EM, Schmitz-Valckenberg S, Pielen A, Puri P, Berk H, Eter N, Wiedemann P et al. Clinical efficacy and safety of ranibizumab versus dexamethasone for central retinal vein occlusion (comrade c): A european label study. *American journal of ophthalmology* 2016;169(258-267).
doi:10.1016/j.ajo.2016.04.020
27. Holz FG, Roider J, Ogura Y, Korobelnik JF, Simader C, Groetzbach G, Vitti R, Berliner AJ, Hiemeyer F, Beckmann K et al. Vegf trap-eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase iii galileo study. *The British journal of ophthalmology* 2013;97(3): 278-284.
doi:10.1136/bjophthalmol-2012-301504

28. Kamei M, Terasaki H, Yoshimura N, Shiraga F, Ogura Y, Grotzfeld AS, Pilz S, Ishibashi T. Short-term efficacy and safety of ranibizumab for macular oedema secondary to retinal vein occlusion in japanese patients. *Acta ophthalmologica* 2017;95(1): e29-e35. doi:10.1111/aos.13196
29. Li F, Sun M, Guo J, Ma A, Zhao B. Comparison of conbercept with ranibizumab for the treatment of macular edema secondary to branch retinal vein occlusion. *Curr Eye Res* 2017;42(8): 1174- 1178. doi:10.1080/02713683.2017.1285943
30. Moon J, Kim M, Sagong M. Combination therapy of intravitreal bevacizumab with single simultaneous posterior subtenon triamcinolone acetonide for macular edema due to branch retinal vein occlusion. *Eye (London, England)* 2016;30(8): 1084-1090. doi:10.1038/eye.2016.96
31. Staurengi G, Lai TYY, Mitchell P, Wolf S, Wenzel A, Li J, Bhaumik A, Hykin PG. Efficacy and safety of ranibizumab 0.5 mg for the treatment of macular edema resulting from uncommon causes. Twelve-month findings from prometheus. *Ophthalmology* 2018. doi:10.1016/j.optha.2017.12.002
32. R. Tadayoni, S. M. Waldstein, F. Boscia, H. Gerding, I. Pearce, S. Priglinger, A. Wenzel, E. Barnes, M. Gekkieva, S. Pilz et al. Individualized stabilization criteria-driven ranibizumab versus laser in branch retinal vein occlusion. *Ophthalmology* 2016;123(6): 1332- 1344. doi:10.1016/j.optha.2016.02.030
33. R. Varma, N. M. Bressler, I. Suner, P. Lee, C. M. Dolan, J. Ward, S. Colman, R. G. Rubio. Improved vision-related function after ranibizumab for macular edema after retinal vein occlusion: Results from the bravo and cruise trials. *Ophthalmology* 2012;119(10): 2108-2118. doi:10.1016/j.optha.2012.05.017

